NCT02383108已完成2 期
A Two-arm, Phase 2/3 Multicentre, Open-label, Randomised Study Evaluating Safety and Antiviral Effect of Current Standard Antiretroviral Therapy Compared to Once Daily Integrase Inhibitor Administered With Darunavir/Ritonavir (DRV/r) in HIV-1 Infected, Virologically Suppressed Paediatric Participants.
PENTA Foundation31 个研究点 分布在 11 个国家目标入组 318 人开始时间: 2016年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 318
- 试验地点
- 31
- 主要终点
- Percentage of patients with HIV-1 RNA ever ≥ 50 c/mL (confirmed within 4 weeks)
研究概览
简要总结
A two-arm, Phase 2/3 multicentre, open-label, randomised study evaluating safety and antiviral effect of current standard antiretroviral therapy compared to once daily integrase inhibitor administered with darunavir/ritonavir (DRV/r) in HIV-1 infected, virologically suppressed paediatric participants.
详细描述
A two arm parallel group, non-inferiority, open-label, multi-centre, randomised controlled trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HIV-1 infected children aged ≥ 12 years old and weighing ≥40kg* at the screening visit
- •Aged 12 to < 18 years old**
- •Parents or guardians, and children where appropriate, willing and able to give informed consent and to adhere to the protocol
- •Children must have all HIV-1 RNA viral loads <50c/mL for at least 12 months with a minimum of two separate results before screening.
- •Children on a 3-drug PI/r or NNRTI containing regimen for at least 24 weeks
- •Children/parents/guardians prepared to switch if randomised to once daily integrase inhibitor + DRV/RTV arm
- •Children and parents prepared to restart the current ART regimen after simplification if viral load restart criteria are met (see Section 5.5)
- •Be affiliated or beneficiary to Health Social security scheme (in countries where this is mandatory)
- •Initially enrolment will be of participants ≥ 12 years old and ≥40kg only. DTG 50 mg will be supplied by ViiV Healthcare.
- •As more data become available on younger children, a protocol amendment is planned to include younger children and/or lower weight bands.
排除标准
- •Receiving or requiring agents with interactions with DRV, RTV, or any once daily integrase inhibitor (Appendix 14)
- •Evidence of resistance to DRV or integrase inhibitors (for participants in clinical sites where resistance testing is standard of care)
- •Previous exposure to integrase inhibitors for more than 2 weeks
- •Intercurrent illness (randomisation can take place after the illness resolves)
- •Creatinine ≥ 1.8ULN or ALT ≥ 5ULN or ALT ≥ 3ULN and bilirubin ≥2ULN at screening.
- •Patients with severe hepatic impairment or unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, or persistent jaundice), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
- •Diagnosis of tuberculosis and on anti-tuberculosis treatment (children can be enrolled after successful tuberculosis treatment)
- •Hepatitis B or Hepatitis C co-infection
- •Pregnancy or risk of pregnancy in girls of child-bearing potential unless committed to taking effective contraception
- •History or presence of known allergy or some other contraindication to the study drugs or their components as described in the SmPC
研究组 & 干预措施
Standard of Care group (SOC)
Active Comparator
triple anti-retroviral therapy including 2 NRTIs + boosted PI/NNRTI
干预措施: SOC (Drug)
DTG+DRV/r
Experimental
NRTI-sparing regimen: Once daily integrase inhibitor (INSTI) + darunavir/ritonavir (DRV/r)
干预措施: DTG +DRV/r (Drug)
结局指标
主要结局
Percentage of patients with HIV-1 RNA ever ≥ 50 c/mL (confirmed within 4 weeks)
时间窗: at any time up to week 48
次要结局
- Change in ART (defined as any change from the ART regimen at randomisation)(at week 0)
- Any adverse event at least possibly related to study drugs or leading to treatment modifications(over 48 weeks)
- All grade 3 or 4 laboratory adverse events(over 48 weeks)
- Occurrence of new resistance mutations(over 48 weeks)
- Changes in CD4 (absolute and percentage)(from baseline to weeks 24 and 48)
- Blood lipids(over 48 weeks)
- Adherence as measured by questionnaire and visual analogue scale(over 48 weeks)
- Percentage of patients with HIV-1 RNA < 50 c/mL(at week 48)
- Date of first menses(over 48 weeks)
- Height(Over 48 weeks)
- Percentage of patients with HIV-1 RNA ≥ 50 c/mL(at week 24)
- Percentage of patients withHIV-1 RNA ≥ 400c/mL(at week 24 and week 48)
- Percentage of patients with any grade 3 or 4 clinical adverse events (particularly lipodystrophy); any grade 3 or 4 laboratory adverse events(over 48 weeks)
- New or recurrent CDC/WHO stage C or severe stage B event or death(over 48 weeks)
- Tanner scales (in participants aged over 8 years)(over 48 weeks)
- Acceptability and quality of life over 48 weeks as assessed by patient completed questionnaires(over 48 weeks)
- Weight(over 48 weeks)
研究者
研究点 (31)
Loading locations...
相似试验
已完成
2 期
Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B InfectionNCT04980482Arbutus Biopharma Corporation43
已完成
2 期
A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected AdultsHIV InfectionsNCT04871113ViiV Healthcare62
已完成
2 期
Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV InfectionChronic Hepatitis CNCT01826981Gilead Sciences359
已完成
2 期
Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV InfectionHepatitis CNCT01909804Gilead Sciences323
已完成
2 期
Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV InfectionHepatitis CNCT01858766Gilead Sciences379